EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma

Kazuto Tajiri iD, Nozomu Muraishi, Eiki Ishizaka, Aiko Murayama, Yuka Hayashi, Ichiro Yasuda iD

Cancers · 21.03.2026 · 18 (6) · 1021

DOI: 10.3390/cancers18061021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 21.03.2026. Verfasst von Kazuto Tajiri und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Atezolizumab plus bevacizumab (Atez/Bev) is a standard treatment for unresectable hepatocellular carcinoma (HCC), but its anti-tumor efficacy remains limited. Combining intrahepatic locoregional treatment (IHLRT) with Atez/Bev has been explored as a strategy to overcome this limitation. This study aimed to clarify the significance of IHLRT in Atez/Bev treatment for unresectable HCC.

Methods

Eighty consecutive patients with unresectable HCC treated with Atez/Bev were retrospectively analyzed. IHLRT was performed in patients with residual viable hepatic lesions amenable to locoregional treatment during Atez/Bev therapy. Anti-tumor response was evaluated by RECIST; and progression-free survival (PFS), overall survival (OS), potential biomarkers, and contributing factors to OS were also assessed.

Results

IHLRT was selectively performed in 20 patients based on individual clinical conditions. Pretreatment characteristics were comparable between patients who did and did not receive IHLRT. Both best and initial tumor responses were superior in the IHLRT group, and PFS was significantly longer (16.2 vs. 8.4 months, p = 0.019), with comparable rates of severe treatment-related adverse events. On multivariate analysis, hepatic reserve function, objective response, neutrophil-to-lymphocyte ratio (NLR) and IHLRT were independent predictors of OS (HR: 2.17, 3.13, 0.58, and 1.62; p = 0.02,

Schlagwörter

Stichwörter der Autor:innen

atezolizumabbevacizumabcombination therapyintrahepatic controllocoregional treatmentneutrophil-lymphocyte ratioobjective response

Autor:innen und Institutionen

  • The Third Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan.

ORCID-Profile: Kazuto Tajiri, Ichiro Yasuda

Zitieren

APA

Tajiri, K., Muraishi, N., Ishizaka, E., Murayama, A., Hayashi, Y., & Yasuda, I. (2026). On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. Cancers, 18(6), 1021. https://doi.org/10.3390/cancers18061021

Vancouver

Tajiri K, Muraishi N, Ishizaka E, Murayama A, Hayashi Y, Yasuda I. On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma. Cancers. 2026;18(6):1021. doi:10.3390/cancers18061021

BibTeX
@article{Tajiri2026,
  author = {Tajiri, Kazuto and Muraishi, Nozomu and Ishizaka, Eiki and Murayama, Aiko and Hayashi, Yuka and Yasuda, Ichiro},
  title = {On-Demand Loco-Regional Treatment for Intrahepatic Lesions Improves Treatment Outcomes in Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {1021},
  doi = {10.3390/cancers18061021}
}
Kostenlos starten →